Cue Biopharma Inc EV/EBIT
¿Qué es el EV/EBIT de Cue Biopharma Inc?
El EV/EBIT de Cue Biopharma Inc es N/A
¿Cuál es la definición de EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT de compañías en Sector Health Care en NASDAQ en comparadas con Cue Biopharma Inc
¿Qué hace Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Empresas con ev/ebit similar a Cue Biopharma Inc
- Carpinienne de Participations tiene EV/EBIT de N/A
- Efficacious Elk Capital tiene EV/EBIT de N/A
- Extraction Oil & Gas tiene EV/EBIT de N/A
- Kiromic BioPharma tiene EV/EBIT de N/A
- Gold State Resources tiene EV/EBIT de N/A
- 2760 tiene EV/EBIT de N/A
- Cue Biopharma Inc tiene EV/EBIT de N/A
- Cannabis Growth Opportunity tiene EV/EBIT de N/A
- Pivotal tiene EV/EBIT de N/A
- Entheon Biomedical tiene EV/EBIT de N/A
- Vinco Ventures tiene EV/EBIT de N/A
- AquaBounty Technologies Inc tiene EV/EBIT de N/A
- Walcott Resources tiene EV/EBIT de N/A